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Introduction.  Australia has been long recognized as punching above its weight in 
biomedical research.  Australian scientists have achieved international recognition 
with the award of a Nobel Prize for Medicine particularly in the area of immunology 
and infectious disease: Sir Howard Florey (1945) for the discovery of penicillin; Sir 
Frank Macfarlane Burnet (1960) for the discovery of acquired immunological 
tolerance; Peter Doherty (1996) for cell mediated immune defence; Barry Marshall 
and Robin Warren (2005) for their discovery of the Helicobacter pylori bacterium 
causing stomach ulcers and gastritis.  Australia boasts a vibrant research community 
with a diverse range of interests in the emerging field of cell therapies. International 
collaboration is actively supported by groups such as the International Society of 
Stem Cell Research, the International Society of Cellular Therapy and the 
Australasian Gene Therapy Society each hosting meetings in Australia this year.  
The fact that few cell therapies have been licenced by the FDA in the US indicates 
the youth of this field. This review showcases the preclinical, translational and clinical 
cell-based gene therapies, vaccines/immunotherapies and regenerative medicines 
that are currently under development in Australia. 
 
(1)  Cell-based Gene Therapy. 
Cell-based gene therapy strategies used in Australia include:(a) corrective gene 
addition to restore dysfunctional gene activity; (b) immunotherapy and cell-based 
vaccines to augment the body’s immune response against a disease; and (c) 
intracellular vaccination which introduces disease modifying or modulating genes 
such as antisense RNA, ribozymes or short interfering RNA. This section outlines 
gene therapy preclinical to clinical studies currently underway in Australia (see Table 
1). 
 
Johnson & Johnson Research P/L Sydney NSW has completed two Phase I gene 
transfer studies for human immunodeficiency virus (HIV) and also commenced a 
Phase II trial.  A study in genetically identical twins, discordant for HIV-1 infection 
was initially performed [1]. CD4+ enriched T cells from the HIV negative twin were 
divided into two equal portions, and transduced with either RRz2 (anti-HIV-1 
ribozyme) or the LNL6 retroviral vector control, expanded and reinfused into the 
respective HIV-1-positive twin. Four patients were treated in the study.  Macpherson 
et al [1] reported this gene therapy approach was safe and feasibile and the long-
term survival of ribozyme (and control) modified T cells within the peripheral blood. 
In another Phase I study, the ability to introduce a potential anti-HIV gene 
therapeutic into hematopoietic progenitor cells (HPC) was examined. Amado et al 
[2]showed the presence and expression of a retroviral vector encoding an anti-HIV-1 
ribozyme in mature hematopoietic cells of different lineages, and de novo T cell 
development ensuing from the gene modified CD34+ HPC. Sustained output of 
vector-containing mature myeloid and T cells was detected even in patients with 
multidrug-resistant infection. In addition, the study showed that the degree of 
persistence of gene-containing cells was dependent on transduced HPC dose. This 
report represented the first demonstration of long-term maintenance of a therapeutic 
transgene in AIDS. 
Johnson & Johnson Pharmaceutical Research & Development with 
L.L.C. Tibotec Pharmaceutical Limited have commenced a “Randomized Phase II, 
double-blind, controlled trial to evaluate the safety and efficacy of autologous CD34+ 
hematopoietic progenitor cells transduced with placebo or an anti-HIV-1 ribozyme 
(OZ1) in patients with HIV-1 infection.” This ongoing study which commenced in 2002 
has accrued 74 patients (G Symonds; personal communication). 
 
The Gene Therapy Unit at The Children’s Hospital Westmead in Sydney NSW 
undertook a clinical study for the correction of the genetic disease X-linked severe 
combined immunodeficiency (SCID-X1).   One SCID-X1 infant with intact natural 
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killer (NK) cells, a variant to the common SCID-X1 phenotype, was treated with 
autologous bone marrow CD34+ HPC that were retrovirally transduced ex vivo with 
human gamma chain (gamma c), an integral component common to many interleukin 
receptors.  A transient recovery in the peripheral blood T cells was accompanied by 
an early weight gain and rotavirus clearance from the gut. However, immune 
reconstitution remained incomplete and the infant receive a bone marrow transplant 
from a matched unrelated donor 26 months after gene therapy.  It was proposed that 
the partial reconstitution was attributed to the relatively low dose of gene-corrected 
HPC re-infused; a viral infection during the early Phase of T cell reconstitution and 
the infant's NK+ phenotype [3]. 
 
The Gene and Stem Cell Therapy Program at the Centenary Institute of Cancer 
Medicine and Cell Biology, NSW and Royal Prince Alfred Hospital have 
performed studies assess the efficacy of various adeno-associated virus (AAV) 
serotypes to transduce mesenchymal stromal cells (MSC) for use as cellular delivery 
vehicles in muscle repair.  A preclinical animal study showed that AAV serotype 2 
was the most efficient in transducing MSC isolated from humans and baboons. 
Baboon MSC transduced with AAV2, retained their potential to differentiate into 
adipocytes in vitro, and engraft injured muscle tissue of diabetic-severe combined 
immunodeficient (NOD-SCID) mice in vivo. The reporter gene was expressed in 
engrafted cells that displayed a muscle fibre morphology for 9 weeks following 
implantation [4]. 
 
(2) Vaccines.   
Cell-based vaccines whether to prevent or treat disease take advantage of the 
immune system’s network of cells and organs.  Cell-based vaccines currently under 
development in Australia include the adoptive transfer of unmodified or gene 
modified immunological effector cells such as cytotoxic T lymphocytes (CTL) or 
natural killer (NK) cells.  Cell-based tumor vaccines may consist of or contain 
autologous or allogeneic tumor cells that may be genetically modified.  Otherwise 
they are based on professional antigen-presenting cells such as dendritic cells (DC) 
loaded with tumor associated antigens (TAA).  Alternatively, DCs may be fused with 
tumor cells or they may be genetically modified to express TAA and/or 
immunomodulatory genes.  Cell-based vaccines are generally classified as cell 
therapies unless they have been gene modified and are classified as medicines.  The 
following summarises the cell-based vaccine studies (preclinical to clinical) currently 
underway in Australia (see Table 1). 
 
The Cancer Immunotherapy Group at the Queensland Institute of Medical 
Research (QIMR) undertook the first clinical application of retrovirally transduced 
melanoma cells [5]. With the Mater Adult Public Hospital they subsequently trialed 
autologous DC cultured ex vivo with irradiated autologous tumor cells, as a treatment 
for patients suffering advanced metastatic melanoma [6].  In this trial, 17 patients 
commenced immunotherapy, 12 of which received all six ‘priming’ vaccinations. Of 
these 12 patients, three had durable complete responses, three had partial 
responses, and the remaining six had progressive disease (WHO criteria). 
Importantly, the clinical results from this trial, and the lack of morbidity associated 
with treatment, have now been replicated in a follow-up study. A randomised, double 
blinded clinical trial using the same treatment for patients with an earlier stage 
metastatic melanoma has commenced. DC immunotherapy trials for other solid 
malignancies including Prostate cancer and Glioblastoma have also been initiated. 
This is in association with Q-Gen P/L at QIMR, a facility for the GMP production of 
Cell Therapies (N Martinez, Q-Gen; personal communication). 
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In a preclinical animal study the Cancer Immunology Program at the Peter 
MacCallum Cancer Centre (Peter Mac), Melbourne, Victoria showed that gene 
modified T cells expressing a chimeric single-chain receptor co-delivering CD28 and 
T cell receptor zeta chain activation signals may be a promising treatment for cancer 
[7].  Primary human T cells were retrovirally transduced to express the chimeric 
receptor reactive with ErbB2.  These modified T cells vigorously responded to  
ErbB2+ tumors in an antigen-specific manner in vitro. When infused into irradiated 
NOD-SCID tumor bearing mice, the modified T cells significantly delayed the growth 
of ErbB2+ human tumors. These studies showed that T cells may be genetically 
redirected to kill tumors. 
In another preclinical mouse study, the Cancer Immunology Program at the 
Peter Mac with the Department of Pathology, University of Melbourne, Parkville, 
Victoria showed that chimeric Fc epsilon receptors combined with tumor specific IgE 
further enhanced the redirection of T cells for cancer gene therapy [8].  Human 
primary T cells were retrovirally transduced with the extracellular domain of Fc 
epsilon RI linked to the hinge and transmembrane domains of Fc gamma RII and the 
cytoplasmic domains of CD28 and T cell receptor zeta chain (chimeric Fc epsilon 
receptor). This study showed that modified T cells, in the presence of tumor-specific 
IgE antibody, can mediate effector function in vitro and in vivo. 
 
The PeterMac including the Centre for Blood Cell Therapies (CBCT) with the 
Ludwig Institute for Cancer Research, Melbourne have commenced a 
translational/Phase 1 study investigating the infusion of autologous T cells retrovirally 
transduced with an anti-Lewis Y (LeY) chimeric receptor in patients with LeY+ 
myeloid malignancies including multiple myeloma (MM).  The anti-LeY chimeric 
surface receptor is composed of a humanised single chain antibody specific for LeY 
which is joined to human CD28 and the CD3-zeta molecules which relay a cancer 
killing T cell response upon binding to LeY on the surface of tumor cells [9, 10, 11]. 
The study will be further amended to allow inclusion of patients with myeloid 
malignancies. 
The PeterMac established the CBCT to support a range of cell and tissue 
manipulation including gene modification under GMP conditions and was the first 
TGA licenced facility in Australia.  In addition to the above study, the CBCT is 
undertaking two further Phase 1 trials: adjuvant monocyte-derived DC vaccination 
(pulsed with autologous myeloma lysate) post autologous stem cell transplant in 
patients with MM; autologous monocyte-derived DC (pulsed with viral peptide) 
immunotherapy for persistent Hepatitis C virus infection (D Wall, personal 
communication). 
 
The Institute of Hematology Royal Prince Alfred Hospital (RPAH) and the 
Cancer Immunology Group, University of Sydney have commenced a 
translational study for the development of a tumor antigen-specific NK cell therapy for 
multiple myeloma and Waldenstrom’s macroglobulinaemia.  In this study the NK-92 
cell line, a potent effector cytotoxic cell line, will be transfected with a gene 
expressing a receptor for human CD106 (VCAM-1) that will enable it to home to the 
bone marrow and to breach the tumor ‘barrier’ which is a major limiting step in 
immune rejection of tumors. At the same time, NK-92 will be transfected with a gene 
expressing a receptor for specific tumor surface marker such as human CD38 that 
will enable it to specifically target and kill the tumor cells [12].  In this ongoing study 
the NK-92 immunotherapy cytotoxicity will be assessed in vitro and clinical efficacy 
against MM will be assessed in vivo (D Sze, personal communication). 
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(3)  Regenerative Medicine.  
Regenerative medicine involves the use of healthy living cells to replace diseased, 
dying or missing cells or tissues.  Cells may be minimally manipulated or expanded in 
cell culture (with or without modification) to obtain a sufficient cell “dose” to provide a 
therapeutic effect.  Table 2 summarises some of the research in regenerative 
medicine from preclinical to clinical studies currently undertaken in Australia. 
 
The Victor Chang Cardiac Research Institute and St Vincent’s Hospital, Sydney 
NSW have recently completed a Phase Ib-IIa interventional study into the treatment 
of chronic refractory ischemic heart disease (IHD) with granulocyte-colony stimulating 
factor (G-CSF) mobilised autologous CD133+ progenitor cells [13, 14, 15, 16].  G-
CSF itself may promote angiogenesis via stem cell or cytokine-related pathways. 
This study assessed the safety and efficacy of: G-CSF to mobilise endothelial 
progenitors in chronic IHD patients [17]; intracoronary infusion of G-CSF mobilised 
CD133+ endothelial progenitor cells to treat chronic IHD.  The administration of G-
CSF was an open-label, uncontrolled intervention.  The intracoronary infusion of G-
CSF mobilised CD133+ cells was a randomised double-blind placebo controlled 
intervention. During the periods of G-CSF administration (2 cycles 3 months apart), 
patients underwent controlled myocardial ‘ischemia-induction’ by supervised exercise 
stress testing.  It was hypothesised that ischemia could induce angiogenic and 
progenitor cell-homing cytokines and facilitate trafficking of the mobilised progenitors 
to the heart.  Patients also underwent leucapheresis immediately after the second 
cycle of G-CSF. Patients were then randomised to receive an intracoronary infusion 
of CD133+ or unselected cells.  Preliminary data analyses have shown provisional 
safety, and an improvement in outcomes as a result of G-CSF administration + 
‘ischemia induction’. Specifically, patients showed significant improvements in 
angina, nitrate use and exercise stress test performance (all p < 0.01) as a result of 
G-CSF administration + ‘ischemia-induction’. Analysis of the intracoronary cell 
infusion data is ongoing (H Tao, personal communication). 
 
The Department of Medicine St Vincent’s Hospital Fitzroy, University of 
Melbourne, and Royal Victorian Eye and Ear Hospital, Melbourne Victoria with 
Columbia University, New York, USA have shown improvement in patients with 
chronic IHD that have received intra-coronary high-dose CD34+ stem cell therapy 
[18].  This study used G-CSF to mobilise CD34+ cells for harvest by leucapheresis 
enabling the intracoronary reinfusion of large CD34+ cell numbers. CD34+ cells were 
separated (Isolex 300) in a GMP facility prior to reinfusion.  All IHD patients showed a 
sustained reduction in anginal symptoms and improved quality of life scores following 
reinfusion. The 12-month follow-up angiography showed significant improvement, 
indicating sustained myocardial neovascularisation. However, complications arose in 
two patients, one developing an acute coronary syndrome and the other a lentigo 
maligna. These results demonstrate the feasibility of G-CSF mobilisation, 
leucapheresis and intracoronary transfer of CD34+ stem cells in patients with chronic 
IHD, but longer-term studies are required to ensure the safety and efficacy of this 
protocol. 
 
The Eskitis Institute for Cell and Molecular Therapies, National Adult Stem Cell 
Centre Griffith University with Princess Alexandra Hospital, Brisbane, QLD are 
exploring the regeneration of human spinal cord injuries in paraplegic patients 
following transplantation with autologous olfactory ensheathing cells into the 
damaged spinal cord.  This trial will test for: adverse reactions from the procedure; 
and whether olfactory ensheathing cells will allow axonal penetration and 
regeneration of the injured spinal cords. Half the patients received the cell implant, 
the control group did not. Human nasal mucosa was obtained by biopsy from the 
nasal septum. Biopsies were processed and the dissociated cells were cultured over 
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4 weeks to build up an adequate supply of ensheathing cells [19]. The study should 
be completed in August 2007 and the results will be published (A Mackay-Sim, 
personal communication). 
 
The Australian Stem Cell Centre in conjunction with the PeterMac in 
Melbourne, Victoria have completed a Phase I study to assess the safety and 
efficacy of transplanting ex vivo expanded autologous CD34+ cells to aid in the 
recovery of patients treated with multiple courses of high dose combination 
chemotherapy for breast cancer [20].  This study showed that ex vivo expanded 
CD34+ cell product under GMP conditions could be administered without adverse 
events or post transplant complications. Ex vivo expanded cells contributed to faster 
rates of neutrophil recovery, significantly fewer episodes of febrile neutropenia and a 
significant reduction in platelet transfusion requirements (D Haylock, personal 
communication). 
 
The Division of Hematology and Hanson Institute, Institute of Medical and 
Veterinary Sciences, Adelaide, South Australia, are undertaking a Phase I trial to 
assess the effect of infused mesenchymal stem cells (MSC) from HLA-identical, 
HLA- haploidentical or unrelated donors in patients with steroid resistant grades II-IV 
acute graft-versus-host disease (GVHD).  Adherent MSC from volunteer bone 
marrow were expanded using a standardised protocol in a GMP facility for 4 – 6 
weeks prior to infusion [21]. Data is currently under evaluation (I Lewis, personal 
communication). 
 
The Diabetes Transplant Unit at Prince of Wales Hospital and University of New 
South Wales in Sydney is developing cell therapies to replace insulin-producing 
cells in insulin-dependent diabetics.  The cells to be grafted are derived from: (a) the 
pancreas of humans who donate their pancreas after death; (b) human embryonic 
stem cells; (c) human stem cells derived from non-embryonic tissues, such as cord 
blood and the fetal pancreas; (d) genetically modified non-pancreatic cell lines, 
especially from the liver; (e) the pancreas of an animal, especially the pig.  Clinical 
trials have commenced with insulin-producing cells isolated from donor human 
pancreas, which have been placed in microcapsules made of alginate to overcome 
the need for anti-rejection therapy [22].  Preclinical studies are being conducted with 
insulin-producing cells isolated from the fetal pig pancreas.  Human embryonic stem 
cells have been derived from spare fertilised eggs, and it is anticipated that attempts 
will be made to make patient-specific embryonic stem cell lines (B Tuch, personal 
communication).  
 
The Ray & Bill Dobney Cell & Tissue Therapies (CTT) facility at Royal Perth 
Hospital, Western Australia is a newly established GMP manufacturing unit is 
conducting two regenerative medicine studies: a Phase I study focused on GVHD 
associated with allogeneic stem cell transplantation; and translational studies 
investigating the utility of MSC in controlling autoimmune and hematological 
disorders.  In the Phase I trial assessing the safety and efficacy of MSC in GVHD, 
MSC harvested from the bone marrow of donors were expanded and co-infused with 
the hemopoietic graft.  The CTT is also conducting a translational study investigating 
the role of MSC as an immunosuppressive therapy for autoimmune and 
hematological disease including immune thrombocytopenic purpura and systemic 
lupus erythematosis and also for chronic lymphocytic leukemia. In conjunction with 
Princess Margaret Hospital, the CTT is assessing the ability of NK cells to treat 
leukemia and lymphoma.  A specific HLA mismatch between donor and recipient 
may prevent both the recurrences of leukemia and GVHD.  The presence of this 
mismatch enables donor NK cells to seek out and destroy any residual leukemic 
cells. This study will examine in vitro methods of preferentially expanding the minor 
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subset of NK cells that are alloreactive to be used as a therapy for treating 
hematological malignancy (M Sturm, personal communication) 
 
The Spine Service, Dept of Orthopaedic Surgery, St. George Clinical School 
UNSW and the Dept of Hematology and Stem Cell Transplantation, St Vincent's 
Hospital, Sydney NSW have designed a randomised, placebo-controlled, double-
blind, Phase I clinical trial to evaluate safety and feasibility of autologous bone 
marrow derived stem cell transplantation into the intervertebral disc to treat disc 
degeneration in patients with low back pain (H Tao, personal communication [23]).   
 
The Institute of Hematology and the Cell and Molecular Therapy Laboratories, 
Royal Prince Alfred Hospital (RPAH) Sydney NSW are designing a Phase I trial to 
standardise the treatment of allogeneic hematopoietic stem cell transplantation 
(HSCT) induced GVHD using mesenchymal stromal cells (MSC).  Whilst there is now 
a moderate experience with the use of MSCs to treat patients with refractory GVHD 
with some success [24], there is variability in the methods of culture, number of cells 
infused and passage number at which the cells are given. One of the greatest 
concerns currently relates to MSC safety owing to an increasing number of studies 
demonstrating that even medium-term culture ex vivo may lead to phenotypic and 
genotypic changes including neoplasia. This study will investigate the issues of cell 
dose and passage number with the view to establishing the optimal combination for 
the treatment of these patients (S Larsen, personal communication). 
  
In a translational study the Department of Pathology University of Melbourne and 
Paediatrics Royal Children's Hospital, Melbourne Victoria are investigating the 
ability of cord blood-derived stem cells to form lung epithelial cells for the treatment of 
lung disease, in particular cystic fibrosis (CF). Unrestricted somatic stem cells 
(USSC) were successfully generated from 3 out of 9 cord blood samples.  USSC 
showed the ability to undergo tri-lineage differentiation (neuronal, bone and 
epithelial).  The differentiated epithelial cells expressed SPC, and at certain time 
points the cystic fibrosis transmembrane conductance regulator (CFTR). If the 
differentiated epithelial cells prove to be functional, and a safe method to engraft 
these cells into the lung can be determined, in the first instance HLA identical sib 
cords will be used to treat the affected sibling with CF. The goal is to eventually move 
to using units of cord blood from unrelated donors from the public cord blood bank, 
which is particularly relevant to older patients with CF (F Zaibak, personal 
communication). 
 
In a preclinical study the Department of Anatomy and Human Biology and the 
Centre for Opthalmology and Visual Science, University of Western Australia 
have enhanced the revascularization (and hence speed of regeneration) of 
transplanted whole muscles by transducing muscles with the vascular endothelial 
growth factor (VEGF) gene and a reporter GFP gene before transplantation, using an 
AAV into the tibialis anterior muscles of adult mice. One month following injection 
whole muscle auto-transplantation was performed. After grafting, GFP expression 
persisted only in a few surviving myofibers in the periphery of the pretreated muscles, 
although abundant VEGF expression was seen in myogenic cells in all grafted 
muscle. Although only small numbers of rAAV-transduced myofibers were present, 
whole muscle grafts preinjected with rAAV were significantly more vascular than 
saline injected and uninjected control muscle grafts. Furthermore, rAAV-injected 
whole muscle transplants showed greater regeneration (myotube formation) 
compared with the uninjected control muscle transplants. This study showed that 
rAAV-mediated VEGF expression persists only in myofibers that survive the necrosis 
induced by muscle transplantation; however, this amount of VEGF significantly 
increased revascularisation and regeneration of a whole muscle transplants [25]. 
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Discussion:  Australian researchers are developing promising cell therapies 
particularly for HIV, myocardial regeneration in chronic ischemic heart disease and to 
promote hematological recovery in patients receiving cancer chemotherapy.  The 
preclinical and translational studies described herein demonstrate the broad interest 
in cell-based gene therapies for the correction of genetic disease, cancer treatment 
and regenerative medicine.  This has been achieved despite several hurdles of the 
industry that are common world-wide including: complex manufacturing processes 
requiring aseptic production with safeguards against adventitious agent 
contamination; the requirement for production to be undertaken in expensive clean 
room facilities of which there are only three publically owned licenced facilities 
currently in operation (another seven are in development) in Australia; the need to 
ensure the products remain genetically stable and do not acquire mutation; a 
complex regulatory environment focused around the Therapeutic Goods 
Administration (TGA; the FDA equivalent in Australia).  However, the future of cell 
and gene therapies Down Under looks promising. 
 
Acknowledgements.  We thank those who responded to a “Request for Information” 
that was distributed among the cell therapies research community and apologise for 
any inadvertent omissions. The names of contributors are highlighted in the text.   
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Immune responses and 
clinical course of GM-CSF 
immunotherapy 
 















Vaccination resulted in the transient 
regression of most metastatic 
lesions. The anti-tumor effects and 
immune response were not 













Determine the safety and 
efficacy of an autologous 
melanoma cell/dendritic cell 











Durable complete clinical 
responses in a Phase I/II trial using 
an autologous melanoma 
cell/dendritic cell vaccine in a 













Immuno-therapy of Cancer 
Using Systemically 
Delivered Gene-Modified 
Human T cells 
 
Evaluate methods of 
redirecting T cells to kill 
tumors using chimeric tumor-
associated antigen (TAA) 
receptor gene modification.   
 




transduction of T 
cells with a 
chimeric receptor 
reactive with the 
ErbB2 TAA 
Chimeric receptor modified T cells 
produced high levels of cytokines, 
proliferated vigorously and 
mediated the specific lysis of 
ErbB2+ tumors.  In NOD-SCID 
tumor bearing mice, the modified T 


















Adoptive Transfer of 
Chimeric Fc epsilon RI 
Receptor Gene-Modified 
Human T Cells for Cancer 
Immuno-therapy 
 
Evaluate methods of 
redirecting T cells to kill 
tumors using in an IgE-
dependent mechanism.   
 




transduction of T 






Adoptive transfer of chimeric 
receptor-T cells incubated with anti-
CD8 IgE mAb significantly 
enhanced the survival of irradiated 
NOD-SCID mice bearing CD8+ 
tumor compared with control mice. 
 
[8] 
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Table 1.   Cell-based Gene Therapy (continued) 
 
 


































Evaluate the tolerability, safety 
and biological parameters of 
an infusion of autologous 
peripheral blood T cells 
transduced with an anti-Lewis 
Y chimeric receptor gene in 








transduction of T 
cells with an anti-
Lewis Y chimeric 
receptor gene 
 
Translational Phase complete- 















Developing a tumor 
antigen-specific natural 
killer cellular therapy. 
 
Sufficient numbers of a 
retargeted NK-92 cells will be 





of NK-92 cells with 
a receptor for 
CD106 (VCAM-1) 
to promote homing 
to the bone 





Cytotoxicity in vitro and efficacy in 
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progenitor cells for the 
treatment of chronic 
IHD.   
 
This study assessed the 
safety and efficacy of: (a) G-
CSF to mobilise endothelial 
progenitors in chronic IHD 
patients; (b) intracoronary 
infusion of G-CSF mobilised 
CD133+ endothelial progenitor 










Preliminary analyses have shown 
provisional safety, and significant 
improvements in angina, nitrate use 
and exercise stress test performance 
(all p < 0.01) as a result of G-CSF 
administration + ‘ischemia-induction’ 
Analysis of the intracoronary cell 


















dose CD34+ stem cells 
in patients with chronic 
IHD: A 12-month follow-
up 
 
This study assessed the 
safety and efficacy of G-CSF 
to mobilise CD34+ cells from 
the bone marrow for harvest 
by leucapheresis enabling the 
intracoronary reinfusion of 
large CD34+ cell numbers in 








All IHD patients showed improvement 
following reinfusion. The 12-month 
follow-up angiography showed 
significant improvement, indicating 
sustained myocardial 
neovascularisation. However, 







Phase I with 










The regeneration of 
human spinal cord 
injuries with olfactory 
glial cells. 
 
This study will assess: the 
safety of the procedure; and 
whether olfactory ensheathing 
cells, harvested from the nose 
of the paraplegic patient, will 

























This study assessed the 
safety and efficacy of 
transplanting ex vivo 
expanded autologous CD34+ 
cells to aid in the recovery of 
patients treated with multiple 
courses of high dose 






CD34+ cells, ex 
vivo culture for 





Ex vivo expanded cells were 
administered without adverse events or 
post transplant complications and 
contributed to faster rates of neutrophil 
recovery, significantly fewer episodes 
of febrile neutropenia and significant 
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cells (MSC) from 
allogeneic donors in 
patients with steroid 




hematopoietic stem cell 
transplantation (HSCT). 
 
To establish the safety and 
efficacy of infusions of HLA-
identical, HLA- haploidentical 
or unrelated MSC on steroid-
resistant acute GVHD. 
 
Isolation of MSC 
from volunteer 
BM, expansion 























islets as a therapy for 
type 1 diabetes 
 
To overcome the need for 
insulin injections in people 
with type 1 diabetes by 
transplanting islets placed in 
microcapsules to prevent the 

























MSC for Allogeneic 
Hemopoietic Stem Cell 
Transplantation 
 
Test for the safety and efficacy 
of MSC harvested from the 
bone marrow of donors to 
improve hemopoietic 
engraftment and reduce 
GVHD when co-infused with 






























Examine the interaction of 
allogeneic cultured MSC and 
















Table 2.  Regenerative Medicine (continued) 





























Natural Killer Cells to 
Treat Leukemia and 
Lymphoma 
 
Investigate in vitro methods 
of expanding a minor subset 
of NK cells that are 
alloreactive for use as a 

























Bone marrow derived 
stem cell 
transplantation  in 
patients with low back 
pain and disc 
degeneration. 
 
This study will assess the 
safety and feasibility of 
autologous bone marrow 
derived stem cells injected 
into the intervertebral disc to 





























Treatment of allogeneic 
HSCT induced GVHD 
using MSC. 
 
This study will investigate 
cell dose and passage 
number with the view to 
establishing the optimal 
combination for the 
treatment of patients with 
refractory GVHD. 
 
Isolation of MSC, 
expansion under 



















Cell therapy for cystic 
fibrosis 
 
To determine if unrestricted 
somatic stem cells (USSC) 
generated from cord blood 
can be used to treat lung 
disease. 
 










USSC were successfully generated 
from 3 out of 9 cord blood samples.  
These cells showed tri-lineage  
differentiation including epithelial cells 
expressing SPC, and at certain time 
points CFTR.  The ability of these cells 
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Growth Factor (VEGF) 
Gene Therapy in 
Skeletal Muscle before 
Transplantation 
Promotes Muscle 
Regeneration.   
 
To determine whether rAAV 
delivered VEGF to skeletal 
muscle prior to 
transplantation promotes 





of mice were 
injected with rAAV 
encoding VEGF 
and GFP followed 














Muscles were sampled 7 days after 
autografting.  Although only small 
numbers of rAAV-transduced 
myofibers were present, whole muscle 
grafts preinjected with rAAV were 
significantly more vascular and showed 
greater regeneration (myotube 
formation) than saline injected and 
uninjected control muscle grafts.  
 
 
[25] 
 
 
 
 
 
 
